Fetzima?

Fetzima is a once-daily extended-release capsule containing levomilnacipran, used to treat major depressive disorder (MDD) in adults [1]. Levomilnacipran is a serotonin-norepinephrine reuptake inhibitor (SNRI) [1].

How does Fetzima work?

Fetzima works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that play a role in mood regulation [1]. By inhibiting the reuptake of these neurotransmitters, the drug enhances their activity in the synaptic cleft.

What is the active ingredient in Fetzima?

The active ingredient in Fetzima is levomilnacipran [1].

How is Fetzima dosed?

Fetzima is taken orally once daily. Dosing typically starts at 40 mg once daily and can be increased to 80 mg or 120 mg once daily, depending on individual patient response and tolerability [1].

What are the potential side effects of Fetzima?

Common side effects of Fetzima include nausea, constipation, hyperhidrosis (excessive sweating), increased heart rate, erectile dysfunction, and decreased libido [1]. More serious, though less common, side effects can include suicidal thoughts and behaviors, serotonin syndrome, increased blood pressure, and urinary hesitancy [1].

What are the risks associated with Fetzima?

Like other SNRIs, Fetzima carries a boxed warning regarding increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults [1]. Patients should be closely monitored for any worsening of depression or emergence of suicidal ideation [1]. Other risks include serotonin syndrome, particularly when used with other serotonergic drugs, and potential withdrawal symptoms if stopped abruptly [1].

When does Fetzima's patent expire?

Information regarding the specific patent expiry dates for Fetzima and its active ingredient, levomilnacipran, can be found on DrugPatentWatch.com [2].

Who manufactures Fetzima?

Fetzima is manufactured by AbbVie [1].